State of the art paper
Tumor necrosis factor inhibitors – state of knowledge
More details
Hide details
Submission date: 2013-04-13
Final revision date: 2013-07-09
Acceptance date: 2013-07-21
Online publication date: 2014-12-22
Publication date: 2014-12-17
Arch Med Sci 2014;10(6):1175-1185
Tumor necrosis factor (TNF) is considered a major proinflammatory cytokine, affecting various aspects of the immune reaction. All five TNF inhibitors currently available on the market (i.e., etanercept, infliximab, adalimumab, certolizumab and golimumab) are top sellers, although indicated only in autoimmune diseases, including rheumatoid arthritis, Crohn’s disease and psoriasis. This article briefly discusses the background and place for TNF inhibitors in modern therapy. The main safety aspects of TNF inhibitor administration are described in particular, with special consideration of the available meta-analyses. Finally, perspectives on the next-generation TNF inhibitors and their use in the clinic are given.
Journals System - logo
Scroll to top